Related Experiment Video
Updated: Jun 11, 2026
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Imaging targeted-agent binding in vivo with two probes.
Journal of Biomedical Optics
|July 10, 2010
Summary
A new method uses dual fluorescent probes to quantify targeted-agent binding rates in vivo. Researchers observed lower epidermal growth factor uptake in pancreas tumors than expected, aiding therapeutic delivery assessment.
Area of Science:
- Biomedical Imaging
- Pharmacokinetics
- Oncology
Background:
- Quantitative imaging of targeted-agent binding rates in vivo is crucial for assessing drug delivery efficacy.
- Current methods often lack precision in determining real-time binding kinetics.
- Developing noninvasive techniques is essential for preclinical and clinical tumor studies.
Discussion:
- Dual-probe injection with targeted and nontargeted fluorescent dyes enables quantitative imaging of binding rate constants.
- Observed lower-than-expected epidermal growth factor uptake in orthotopic xenograft pancreas tumors (2.3 x 10(-5) s(-1)) compared to normal pancreas (3.4 x 10(-5) s(-1)).
- This discrepancy highlights potential challenges in targeted therapy delivery to pancreatic tumors.
Key Insights:
- Demonstrated a novel approach for in vivo quantitative imaging of targeted-agent binding rates.
- Provided quantitative data on epidermal growth factor receptor binding in pancreas tumors.
- Established a method for noninvasive assessment of tumor receptor targeting.
Outlook:
- This technique can guide the development and optimization of targeted therapies.
- Enables prediction of contrast, spatial localization, and therapeutic efficacy.
- Facilitates personalized medicine approaches in oncology by assessing individual tumor responses.
